Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling.

Nguyen KB, Spranger S.

J Cell Biol. 2020 Jan 6;219(1). pii: e201908224. doi: 10.1083/jcb.201908224.

PMID:
31816057
2.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).

Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I.

J Immunother Cancer. 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3. Review.

3.

Tissue Site and the Cancer Immunity Cycle.

Horton BL, Fessenden TB, Spranger S.

Trends Cancer. 2019 Oct;5(10):593-603. doi: 10.1016/j.trecan.2019.07.006. Epub 2019 Aug 13. Review.

PMID:
31706507
4.

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.

Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF.

J Immunother Cancer. 2019 Nov 8;7(1):295. doi: 10.1186/s40425-019-0780-0.

5.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

6.

Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy.

Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, Wittrup KD.

Sci Transl Med. 2019 Jun 26;11(498). pii: eaaw2614. doi: 10.1126/scitranslmed.aaw2614.

PMID:
31243150
7.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

8.

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF.

Clin Cancer Res. 2019 May 15;25(10):3074-3083. doi: 10.1158/1078-0432.CCR-18-1942. Epub 2019 Jan 11.

PMID:
30635339
9.

WNT Signaling in Cancer Immunosurveillance.

Galluzzi L, Spranger S, Fuchs E, López-Soto A.

Trends Cell Biol. 2019 Jan;29(1):44-65. doi: 10.1016/j.tcb.2018.08.005. Epub 2018 Sep 13. Review.

PMID:
30220580
10.

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion.

Horton B, Spranger S.

Immunity. 2018 Jul 17;49(1):11-13. doi: 10.1016/j.immuni.2018.07.001.

11.

A team effort: natural killer cells on the first leg of the tumor immunity relay race.

Fessenden TB, Duong E, Spranger S.

J Immunother Cancer. 2018 Jul 9;6(1):67. doi: 10.1186/s40425-018-0380-4.

12.

Impact of oncogenic pathways on evasion of antitumour immune responses.

Spranger S, Gajewski TF.

Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12. Review.

13.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2. Review.

14.

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF.

Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.

15.

Genotype and phenotype spectrum of NRAS germline variants.

Altmüller F, Lissewski C, Bertola D, Flex E, Stark Z, Spranger S, Baynam G, Buscarilli M, Dyack S, Gillis J, Yntema HG, Pantaleoni F, van Loon RL, MacKay S, Mina K, Schanze I, Tan TY, Walsh M, White SM, Niewisch MR, García-Miñaúr S, Plaza D, Ahmadian MR, Cavé H, Tartaglia M, Zenker M.

Eur J Hum Genet. 2017 Jun;25(7):823-831. doi: 10.1038/ejhg.2017.65. Epub 2017 May 3.

16.

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Spranger S, Dai D, Horton B, Gajewski TF.

Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.

17.

Acute Liver Failure Meets SOPH Syndrome: A Case Report on an Intermediate Phenotype.

Kortüm F, Marquardt I, Alawi M, Korenke GC, Spranger S, Meinecke P, Kutsche K.

Pediatrics. 2017 Jan;139(1). pii: e20160550. doi: 10.1542/peds.2016-0550.

18.

Innate immune signaling and regulation in cancer immunotherapy.

Corrales L, Matson V, Flood B, Spranger S, Gajewski TF.

Cell Res. 2017 Jan;27(1):96-108. doi: 10.1038/cr.2016.149. Epub 2016 Dec 16. Review.

19.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

20.

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.

Supplemental Content

Loading ...
Support Center